Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656317 | 0.85 | KMT2A (0.42) | KMT2AMEN1HTTSMN1; SMN2SLC6A2 | |
| SCHEMBL2026331 | 0.78 | KCNH2 (0.66) | CYP1A2CYP3A4CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL2026333 | 0.78 | KCNH2 (0.66) | CYP1A2CYP3A4CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL2026335 | 0.78 | KCNH2 (0.66) | CYP1A2CYP3A4CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL14864559 | 0.76 | GRIN1 (0.41) | KMT2AMEN1SLC6A2SLC6A3KCNH2 | |
| SCHEMBL29670413 | 0.72 | ADRB1 (0.53) | KMT2AMEN1HTTSMN1; SMN2KCNH2 | |
| SCHEMBL22640101 | 0.72 | KMT2A (0.65) | KMT2AMEN1HTTSMN1; SMN2SLC6A2 | |
| SCHEMBL22639927 | 0.72 | KMT2A (0.65) | KMT2AMEN1HTTSMN1; SMN2SLC6A2 | |
| SCHEMBL14412442 | 0.71 | KMT2A (0.71) | KMT2AMEN1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12576743 | 0.70 | KCNH2 (0.72) | KMT2ASLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | KMT2A 410/4885MEN1 2505/4885HTT 578/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KMT2A 701/4885MEN1 3627/4885HTT 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.